Episode 62
Biotech Hangout
00:00
Replimium: The Biggest Stock Mover of the Conference
Rob Caufen: Replimium was the biggest stock mover of ASCO. He says they had a 34% response rate in patients who'd failed both, um, PD1s and CTLA4s. Big Cara's EGFR by TGF beta also caught people's attention; it may make sense when you don't have HPV involvement.
Transcript
Play full episode
